Scientific deep-dive
What Is Survodutide? The Glucagon/GLP-1 Dual Agonist in Phase 3
Survodutide is an investigational glucagon/GLP-1 dual agonist with phase 3 obesity data published in 2026. We cover the mechanism, the trial evidence in obesity and MASH, why no head-to-head against tirzepatide exists, and why there is no dose to follow.
Survodutide is an investigational once-weekly glucagon/GLP-1 receptor dual agonist from Boehringer Ingelheim and Zealand Pharma. It reached a phase 3 obesity readout published in the New England Journal of Medicine in 2026 [1], on top of a phase 2 dose-finding trial in The Lancet Diabetes & Endocrinology [2] and a separate phase 2 trial in MASH with fibrosis [3]. It is not approved anywhere, and there is no prescription or pharmacy route to it.
The same two receptors as mazdutide
Survodutide and mazdutide target the identical receptor pair — glucagon plus GLP-1 — which makes them the clearest available comparison of how far that combination can go. The difference is regulatory, not mechanistic: mazdutide is approved in China, survodutide is not approved anywhere yet.
Against tirzepatide, the difference is mechanistic. Tirzepatide pairs GLP-1 with GIP; survodutide pairs it with glucagon. The glucagon arm is associated with increased energy expenditure and reduced liver fat rather than additional insulin secretion, which is also why survodutide has been trialed specifically in liver disease [3] — an indication GIP-based drugs are not primarily aimed at.
Where the evidence stands
- Obesity, phase 3: survodutide once weekly in adults with obesity, published in NEJM in 2026 [1].
- Obesity, phase 2: a randomized, double-blind, placebo-controlled dose-finding trial [2] — the study that established the dose range carried into phase 3.
- MASH with fibrosis, phase 2: a separate randomized trial [3], reflecting the liver-directed rationale for the glucagon arm.
For how survodutide sits alongside the other compounds in the same wave, see our pipeline roundup covering survodutide, MariTide and ecnoglutide.
There is no survodutide dose to follow
Because it is unapproved, there is no labeled dose and no dose chart. The doses that appear in the phase 2 dose-finding publication are exactly that — the range being tested, under supervision, to determine what should go forward. They are not a regimen, and material sold as “survodutide peptide” is unapproved product of unverified identity rather than a trial drug.
Frequently Asked Questions
References
- 1.le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. 2026. PMID: 42253238.
- 2.le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024. PMID: 38330987.
- 3.Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024. PMID: 38847460.
Related research
What Is Mazdutide? The Obesity Drug Approved in China, Not the US
Mazdutide is a glucagon/GLP-1 dual agonist approved in China for weight management but unavailable in the US. What the approval authorizes, how it differs from tirzepatide and retatrutide, and why an approval abroad doesn't make a US-sold vial legitimate.
6 min read
Mounjaro Body Odor: The Evidence and the One Red Flag
Does Mounjaro cause body odor? Tirzepatide doesn't act on sweat glands — keto breath, dehydration, and dry mouth do. The honest mechanisms and the DKA red flag.
9 min read
What is GIP? GIP Receptor Explained (And Why Mounjaro/Zepbound Activate It Alongside GLP-1)
GIP (glucose-dependent insulinotropic polypeptide) is a gut hormone that drives, with GLP-1, the post-meal incretin effect. Tirzepatide (Mounjaro, Zepbound) is the first approved dual GIP/GLP-1 agonist and beat semaglutide in SURPASS-2.
13 min read
Beyond Wegovy and Zepbound: Three Pipeline GLP-1 Drugs to Watch
Three challenger GLP-1 drugs not made by Lilly or Novo: survodutide (Boehringer Ingelheim and Zealand), maridebart cafraglutide (Amgen's MariTide), and ecnoglutide (Sciwind). This guide covers the published phase 2 and 3 data and mechanisms for each, and where they fit.
11 min read
GLP-1 Pipeline Tracker: Every Next-Gen Weight-Loss Drug in Development (2026)
A tracker of next-generation GLP-1 and incretin drugs: retatrutide, CagriSema, MariTide, survodutide, amycretin, mazdutide, ecnoglutide and the approved oral pill orforglipron (Foundayo), with stage and peak reported weight loss.
7 min read
Survodutide for Fatty Liver: What the Phase 3 Nature Medicine Trial Shows
In the phase 3 SYNCHRONIZE-MASLD trial, survodutide 6.0 mg cut liver fat by at least 30% in 68.5% of adults at week 48, versus 28.6% on placebo. What that means, what the biopsy data add, and what the trial cannot show about scarring or liver outcomes.
8 min read
Where to get GLP-1 safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
CoreAge Rx
Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Read full review →Pricing Compare
Get started →Pricing Compare
Get started →Gala
Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping
Read full review →Pricing Compare
Get started →